|1.||Snutch, Terrance P: 14 articles (07/2015 - 01/2002)|
|2.||Zamponi, Gerald W: 14 articles (06/2015 - 07/2002)|
|3.||Todorovic, Slobodan M: 13 articles (07/2015 - 08/2006)|
|4.||Lory, Philippe: 9 articles (02/2016 - 08/2002)|
|5.||Jevtovic-Todorovic, Vesna: 9 articles (04/2014 - 08/2006)|
|6.||Gadotti, Vinicius M: 6 articles (06/2015 - 01/2011)|
|7.||Cain, Stuart M: 6 articles (05/2014 - 01/2009)|
|8.||Lee, Jae Yeol: 6 articles (03/2014 - 10/2006)|
|9.||Uebele, Victor N: 6 articles (02/2014 - 06/2009)|
|10.||Nelson, Michael T: 6 articles (10/2013 - 12/2006)|
|1.||Hypertension (High Blood Pressure)
01/01/2014 - "It is not clear whether the protective effects of T-type calcium channel blockers (T-type CCBs) on renal function are better than those of L-type CCBs or renin-angiotensin system (RAS) antagonists in patients with hypertension. "
04/01/2015 - "Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension."
04/01/2008 - "T-type calcium channel blockers have been previously shown to protect glomeruli from hypertension by regulating renal arteriolar tone. "
11/01/2005 - "Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension."
08/01/1998 - "Alterations of both L- and T-type calcium channels are involved in the development of hypertension. "
07/01/2002 - "It is not known if T-type calcium-channel blockade is superior to L-type calcium-channel blockade in patients with stable angina pectoris. "
02/01/1998 - "The objective of this study was to evaluate the efficacy, tolerability, and safety of mibefradil, a new selective T-type calcium channel blocker, in patients with chronic stable angina pectoris receiving concomitant beta-blocker therapy. "
08/21/1997 - "The safety and tolerability of mibefradil, a selective T-type calcium channel antagonist, were evaluated in 3,430 patients with essential hypertension and chronic stable angina pectoris treated in 15 double-blind placebo and active-controlled clinical trials and 2 open-label, long-term safety studies. "
06/01/1998 - "The pool of controlled clinical studies on mibefradil, a new selective T-type calcium channel blocker, for the treatment of chronic stable angina pectoris was analysed to determine the effects in subgroups of patients defined by age, gender, body weight and common co-existing conditions. "
05/01/2007 - "Recent studies have strongly implicated low voltage-activated/T-type calcium channels (T-channels) in the etiology of epilepsy. "
05/01/2014 - "We also review the mechanisms of action of the current AEDs with known effects on T-type calcium channels and discuss novel compounds that are being investigated as new treatments for epilepsy. "
05/01/2014 - "Low threshold T-type calcium channels as targets for novel epilepsy treatments."
07/01/2013 - "T-type calcium channels in burst-firing, network synchrony, and epilepsy."
04/01/2004 - "Selective inhibition of T-type calcium channels by organic blockers may have clinical importance in some forms of epilepsy. "
09/01/2011 - "Based on both basic and clinical studies, the possibility is emerging that T-type calcium channel blockers that transit into the central nervous system may have therapeutic potentials for tremor disorders."
02/01/2011 - "The present study aimed to study the effects of a range of T-type calcium channel blockers in a parkinsonian tremor model in rats. "
09/01/2011 - "Several T-type calcium channel blockers effectively suppressed experimental tremors that have been suggested to originate from either the cerebellum or basal ganglia. "
09/01/2011 - "Here, we highlight recent advances in our understanding of T-type calcium channel regulation and their implications for tremor disorders. "
09/01/2011 - "T-type calcium channel as a new therapeutic target for tremor."
01/01/2015 - "Expression and Regulation of Cav3.2 T-Type Calcium Channels during Inflammatory Hyperalgesia in Mouse Dorsal Root Ganglion Neurons."
11/01/2009 - "Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice."
05/01/2004 - "450 mg/kg) an anti-epileptic and relatively selective T-type calcium channel blocker elicited a near complete reversal of mechanical allodynia/hyperalgesia. "
02/01/2013 - "T-type calcium channels encoded by the Ca(V)3.2 isoform are expressed in nociceptive primary afferent neurons where they contribute to hyperalgesia and thus are considered as a potential therapeutic target to treat pathological pain. "
11/12/2008 - "Ethosuximide, a T-type calcium channel blocker, eliminated busting in lesioned thalamic slices and attenuated lesion-induced hyperalgesia and allodynia. "
|5.||GABA-A Receptors (GABA(A) Receptor)
|6.||L-Type Calcium Channels (Dihydropyridine Receptor)
|7.||(1S,2S)- 2- (2- (N- ((3- benzimidazol- 2- yl)propyl)- N- methylamino)ethyl)- 6- fluoro- 1,2,3,4- tetrahydro- 1- isopropyl- 2- naphtyl cyclopropanecarboxylate dihydrochloride
|8.||Proteins (Proteins, Gene)
|3.||Drug Therapy (Chemotherapy)